Involvement of Plasma Melatonin in Medication-Overuse Headache: A Cross-Sectional Study

Abstract

Objectives Patients with medication-overuse headache (MOH) are often complicated with anxiety, depression, and sleep disorders and are associated with dependence behavior and substance abuse. Melatonin has physiological properties including analgesia, regulation of circadian rhythms, soporific, and antidepressant and affects drug preference and addiction. This study aimed to investigate the role of melatonin in MOH compared with episodic migraine (EM) and healthy controls and to verify the relationship between plasma melatonin levels and psychiatric symptoms. Methods Thirty patients affected by MOH, 30 patients with EM, and 30 matched healthy controls were enrolled. All subjects completed a detailed headache questionnaire and scales including the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index, the Leeds Dependence Questionnaire. Melatonin levels in plasma samples were measured by enzyme immunoassay method. Results The levels of plasma melatonin were significantly different among 3 groups of subjects (MOH, 7.74 [5.40–9.89]; EM, 9.79 [8.23–10.62]; Control, 10.16 [8.60–17.57]; H = 13.433; P = 0.001). Significantly lower levels of melatonin were found in MOH patients compared with healthy controls (P = 0.001). The level of plasma melatonin inversely correlated with the scores of HADS-Anxiety (r = −0.318, P = 0.002), HADS-Depression (r = −0.368, P < 0.001), Pittsburgh Sleep Quality Index (r = −0.303, P = 0.004), and Leeds Dependence Questionnaire (r = −0.312, P = 0.003). Conclusions This study innovatively detects the plasma melatonin levels in MOH patients and explores the association between melatonin levels and psychiatric symptoms. Melatonin may be potential complementary therapy in the treatment of MOH considering its comprehensive role in multiple aspects of MOH.